Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease

Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE ε4 Allele

“…Our findings are in keeping with findings from other investigators (Doecke et al, 2012 ; Hu et al, 2012 ; Soares et al, 2012 ; O’Bryant et al, 2013 ; Burnham et al, 2014 ). In the Australian Imaging Biomarker and Lifestyle study, PP levels were elevated 1.54-fold in AD dementia cases compared to cognitively normal controls (Doecke et al, 2012 ). In AD Neuroimaging Initiative samples/cohorts plasma, PP levels were higher in AD dementia or MCI cases compared to controls (Kiddle et al, 2012 ; Soares et al, 2012 ).…”

Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE ε4 Allele

“…Our findings are in keeping with findings from other investigators (Doecke et al, 2012 ; Hu et al, 2012 ; Soares et al, 2012 ; O’Bryant et al, 2013 ; Burnham et al, 2014 ). In the Australian Imaging Biomarker and Lifestyle study, PP levels were elevated 1.54-fold in AD dementia cases compared to cognitively normal controls (Doecke et al, 2012 ). In AD Neuroimaging Initiative samples/cohorts plasma, PP levels were higher in AD dementia or MCI cases compared to controls (Kiddle et al, 2012 ; Soares et al, 2012 ).…”

Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients

“…In accordance with our present results, several reports based on genome-wide association studies have shown upregulation of the IL-10 pathway in AD brains [16,17]. Furthermore, several previous studies have found increased CSF and blood levels of IL-10 in AD patients compared to healthy controls [9,18,19,20]. Indeed, IL-10 serum levels have been associated with the degree of cognitive decline and cortical atrophy in AD patients and as a consequence many authors have considered IL-10 as a potential marker of disease progression [21].…”

Distinct alterations of adiponectin, FGF-21 and IGFBP-2 link dysmetabolism with cognitive decline across the Alzheimer’s disease spectrum

“…Serum IGFBP-2 levels differed between groups across the AD spectrum, with SCD and most importantly AD participants presenting higher levels compared to controls. This observation is in accordance with previous reports indicating that a clinical diagnosis of AD is associated with higher concentrations of IGFBP-2 in the blood or CSF [25–27, 30–33, 35, 54, 55]. Recent proteomics data pinpoint IGFBP-2 as an early AD biomarker.…”

Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE ε4 Allele

“…Our findings are in keeping with findings from other investigators (Doecke et al, 2012 ; Hu et al, 2012 ; Soares et al, 2012 ; O’Bryant et al, 2013 ; Burnham et al, 2014 ). In the Australian Imaging Biomarker and Lifestyle study, PP levels were elevated 1.54-fold in AD dementia cases compared to cognitively normal controls (Doecke et al, 2012 ). In AD Neuroimaging Initiative samples/cohorts plasma, PP levels were higher in AD dementia or MCI cases compared to controls (Kiddle et al, 2012 ; Soares et al, 2012 ).…”

Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients

“…In accordance with our present results, several reports based on genome-wide association studies have shown upregulation of the IL-10 pathway in AD brains [16,17]. Furthermore, several previous studies have found increased CSF and blood levels of IL-10 in AD patients compared to healthy controls [9,18,19,20]. Indeed, IL-10 serum levels have been associated with the degree of cognitive decline and cortical atrophy in AD patients and as a consequence many authors have considered IL-10 as a potential marker of disease progression [21].…”

Distinct alterations of adiponectin, FGF-21 and IGFBP-2 link dysmetabolism with cognitive decline across the Alzheimer’s disease spectrum

“…Serum IGFBP-2 levels differed between groups across the AD spectrum, with SCD and most importantly AD participants presenting higher levels compared to controls. This observation is in accordance with previous reports indicating that a clinical diagnosis of AD is associated with higher concentrations of IGFBP-2 in the blood or CSF [25–27, 30–33, 35, 54, 55]. Recent proteomics data pinpoint IGFBP-2 as an early AD biomarker.…”

Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE ε4 Allele

“…Our findings are in keeping with findings from other investigators (Doecke et al, 2012 ; Hu et al, 2012 ; Soares et al, 2012 ; O’Bryant et al, 2013 ; Burnham et al, 2014 ). In the Australian Imaging Biomarker and Lifestyle study, PP levels were elevated 1.54-fold in AD dementia cases compared to cognitively normal controls (Doecke et al, 2012 ). In AD Neuroimaging Initiative samples/cohorts plasma, PP levels were higher in AD dementia or MCI cases compared to controls (Kiddle et al, 2012 ; Soares et al, 2012 ).…”

Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients

“…In accordance with our present results, several reports based on genome-wide association studies have shown upregulation of the IL-10 pathway in AD brains [16,17]. Furthermore, several previous studies have found increased CSF and blood levels of IL-10 in AD patients compared to healthy controls [9,18,19,20]. Indeed, IL-10 serum levels have been associated with the degree of cognitive decline and cortical atrophy in AD patients and as a consequence many authors have considered IL-10 as a potential marker of disease progression [21].…”

Distinct alterations of adiponectin, FGF-21 and IGFBP-2 link dysmetabolism with cognitive decline across the Alzheimer’s disease spectrum

“…Serum IGFBP-2 levels differed between groups across the AD spectrum, with SCD and most importantly AD participants presenting higher levels compared to controls. This observation is in accordance with previous reports indicating that a clinical diagnosis of AD is associated with higher concentrations of IGFBP-2 in the blood or CSF [25–27, 30–33, 35, 54, 55]. Recent proteomics data pinpoint IGFBP-2 as an early AD biomarker.…”